Canada: Good News For The Biotech Industry – Patent Eligibility Of Myriad Isolated DNA And Methods Of Screening Claims Confirmed After Supreme Court’s Mayo Ruling

Last Updated: August 21 2012
Article by Carmela DeLuca

On August 16, 2012, the U.S. Federal Circuit Court of Appeals issued its judgment in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Myriad) partly overturning the district court's summary judgment that Myriad's claims were drawn to patent ineligible subject matter and affirmed Myriad's right to patent isolated DNA of BRCA1 and BRCA2, two genes linked to breast and ovarian cancer. The lawsuit had alleged that patents on human genes violate the First Amendment and are unpatentable as "products of nature."  

This is the Federal Circuit's second decision after the case was remanded back to the Federal Circuit for further consideration in light of the Supreme Court's ruling in Mayo Collaborative Services v. Prometheus Laboratories (Mayo).

On the merits, the Federal Circuit reversed the district court's decision that Myriad's composition claims to "isolated" DNA molecules are patent ineligible products of nature under § 101. The court also reversed the district court's decision that Myriad's method claim to screening potential cancer therapeutics via changes in cell growth rates of transformed cells is directed to patent ineligible scientific principle. However, they did affirm the court's decision that Myriad's method claims directed to "comparing" or "analyzing" DNA sequences are patent ineligible as such claims include no transformative steps and cover only patent ineligible abstract mental steps.

Regarding the challenged claims to isolated DNAs, the Federal Circuit clearly indicated that whether limited to cDNAs or not (cDNA is a type of artificially produced DNA), isolated DNAs are directed to patent eligible subject matter under § 101 adding "permitting patents on isolated genes does not pre-empt a law of nature. A composition of matter is not a law of nature." (Myriad, pg. 51)

Importantly for diagnostic method claims, the Federal Circuit reiterated its previous reasoning with respect to the challenged screening claim. The screening claim required in addition to the step of comparing the cells' growth rates, the steps of growing transformed cells, and determining those growth rates. The Federal Circuit relied on the fact that those steps were transformative stating: "Although the Court has held that certain transformative steps are not necessarily sufficient under § 101 if the recited steps only rely on natural laws, we once again even in light of Mayo, arrive at the same conclusion of patent eligibility because at the heart of the claim is a transformed cell, which is made by man, in contrast to a natural material." (Myriad, pgs. 55 and 56)

The Federal Circuit stated the claim does do more than simply state a law of nature. It applies a law of nature. The Federal Circuit recognized that all activity, whether chemical, biological, or physical, relies on natural laws. However they stated that the challenged claim applies certain steps to transformed cells that are a product of man, not of nature. Performing "operations, even known types of steps, on, or to create, novel, i.e., transformed subject matter is the stuff of which most process or method invention consists. In situations where the objects or results of such steps are novel and nonobvious, they should be patent-eligible." (Myriad, pg. 61)

However, regarding the Myriad claims that include only the step of "comparing" or "analyzing" two gene sequences, the Federal Circuit reiterated such claims fall outside of the scope of § 101 as they claim only abstract mental processes.

The Federal Circuit's reasoning is clear and informative. "This claim thus recites nothing more than the abstract mental steps necessary to compare two different nucleotide sequences: one looks at the first position in a first sequence; determines the nucleotide sequence at that first position; looks at the first position in a second sequence; determines the nucleotide sequence at that first position; determines if the nucleotide at the first position in the first sequence and the first position in the second sequence are the same or different, wherein the latter indicates an alteration; and repeats the process for the next position... Myriad's claims do not apply the step of comparing two nucleotide sequences in a process. Rather, the step of comparing two DNA sequences is the entire process that is claimed." (Myriad, emphasis added; pg. 57)

The Federal Circuit rejected Myriad's attempt to read into its method claims the additional steps of (1) extracting DNA from a human sample, and (2) sequencing the BRCA DNA molecule, which Myriad had argued necessarily precede the step of comparing nucleotide sequences. The Federal Circuit responded that the "claims themselves, however, do not include either of these steps. The claims do not specify any action prior to the step of 'comparing' or 'analyzing' two sequences; the claims recite just the one step of 'comparing' or 'analyzing.' Moreover, those terms' plain meaning does not include Myriad's proposed sample-processing steps; neither comparing nor analyzing means or implies 'extracting' or 'sequencing' DNA or otherwise 'processing' a human sample."  (Myriad, pg. 58)

The case is instructive for drafting patent eligible biotech process claims and patent claims in general. As first identified in Bilski, incorporating transformative steps is important for patent eligibility. Application of a law of nature in a process is also vital for patent eligibility.

Seemingly in recognition of the importance of patents to the biotech industry, the majority opinion stated that "patents on life saving material and processes, involving large amounts of risky investment, would seem to be precisely the types of subject matter that should be the subject to the incentives of exclusive rights" adding that "disapproving of patents on medical methods and novel biological molecules are policy questions best left to Congress." (Myriad, pg. 18)

The case is good news for the biotech industry which has been saddled with uncertainty and difficulties when obtaining patent protection for its biological process inventions. Hopefully the decision ushers in a more consistent approach to determining patent eligibility of biologically related patents both at the U.S. patent office and in the courts.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Carmela DeLuca
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.